A genetic contribution to the development of systemic lupus erythematosus (SLE) is well established. Several genome-wide linkage scans have identified a number of putative susceptibility loci for SLE, some of which have been replicated in independent samples. This study aimed to identify the regions showing the most consistent evidence for linkage by applying the genome scan meta-analysis (GSMA) method. The study identified two genome-wide suggestive regions on 6p21.1-q15 and 20p11-q13.13 (P-value ¼ 0.0056 and P-value ¼ 0.0044, respectively) and a region with P-valueo0.01 on 16p13-q12.2. The region on chromosome 6 contains the human leukocyte antigen cluster, and the chromosome 16 and 20 regions have been replicated in several cohorts. The potential importance of the identified genomic regions are also highlighted. These results, in conjunction with data emerging from dense single nucleotide polymorphism typing of specific regions or future genome-wide association studies will help guide efforts to identify the actual predisposing genetic variation contributing to this complex genetic disease.
Systemic lupus erythematosus (SLE, [MIM] 152700) is the prototypic systemic autoimmune disease with manifestations that can affect virtually any organ system. SLE occurs in women nearly 10 times more frequently than in men and disease prevalence varies strikingly across different ethnic groups. The familial aggregation of SLE suggests a strong genetic contribution, with a 20-to 40-fold increased risk of disease among siblings of an affected individual compared to the general population. 1 Several independent genome scans in multiplex SLE families have identified a large number of genomic regions that may harbor susceptibility genes (reviewed by Tsao 2 ). Although a comparison of these genome scans suggests a number of overlapping regions of linkage, many regions providing evidence of linkage in individual studies do not appear to be supported by results of other genome scans. There are a number of possible reasons for such inconsistency, including genetic or other sources of heterogeneity (e.g., differences in phenotypic characteristics), stochastic fluctuation where some samples get a larger dose of families with a particular predisposing gene, whereas others do not, and small sample sizes resulting in reduced power and spurious findings.
Meta-analysis can be a powerful and useful tool for assessing the consistency of linkage evidence across studies, particularly when differences, such as the specific markers or statistical methods employed make it difficult to directly pool results across studies. In the current study we use the genome scan meta-analysis (GSMA) method 3, 4 to combine linkage results from all genome screens for SLE performed to date. The GSMA method is designed to deal with variation in study designs, analysis methods and marker densities used in different genome scans, and no original genotypes or family data are required. The GSMA has been applied successfully to genome scans in several diseases, including other autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. [5] [6] [7] For each study in a GSMA the genome is divided into distinct bins of approximately equal genetic distance and the bins are ranked according to the maximum evidence of linkage within each bin. The ranks that can be weighted by a study-specific factor are then summed across studies for each bin. Weighting accounts for the relative sizes of individual studies such that smaller, lower-powered studies have a smaller influence on the overall results. Bins with high summed ranks (SR) indicate evidence for linkage across several studies, and significance levels are calculated by permutation tests using the GSMA program. 8 A total of 12 published genome scans of SLE families were identified through review of the literature and through a PubMed search. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Only original genome scan results were considered, whereas partial scans and follow-up studies in candidate regions were excluded. Some studies were performed on expanded, nonindependent collections of families by the same research group. Authors of identified studies were contacted by telephone and/or e-mail and invited to contribute detailed results required for the meta-analysis (i.e., full multipoint non-parametric results across the entire genome). Four groups agreed to participate in the meta-analysis. The Oklahoma Medical Research Foundation (OMRF), University of Minnesota (UMN) and Uppsala University (UU) groups provided complete genome-wide results, as well as complete results for the subgroup of Caucasian families. The University of California at Los Angeles (UCLA) group provided complete data for the Caucasian subgroup of families and the combined results were derived from published tables. 17 These groups provided the most recent data that they had with their continued accumulation of families, which often included a larger set of families compared to the published studies.
Three additional independent studies were derived from publications: a Finnish study, 19 a study from the University of Southern California (USC), 10 and a Hispanic cohort collected by the OMRF group. 20 Other published studies presented substantial overlap in the patients included and were thus not considered. 15, 16 We also performed GSMA in the subgroup of Caucasian samples using the results provided by four groups (UMN, OMRF, UCLA and UU) and the complete genome-wide data extracted from graphs published in the Finnish study. 19 The USC study 10 was excluded from this analysis because it did not present genome-wide results restricted to Caucasian families.
The seven independent SLE studies included in the GSMA are summarized in Table 1 . Together, the data consist of 597 families (57% of Caucasian ethnicity) with 1332 SLE-affected individuals. GSMA was performed weighting each study by the square root of the number of affected individuals, scaled by the mean number among studies (Table 1) . Genome-wide results for linkage ( Figure 1) show that four bins achieved SR P-values of P SR o0.01, and nine bins had P SR o0.05, whereas only 1.2 and six bins, respectively, are expected to exceed these SR thresholds by chance.
Two bins (Table 2 ) achieved suggestive evidence for linkage (P SR o0.00777), which was the empirical P-value derived from simulation, but no bins met the estimated threshold for genome-wide significance (P SR o0.00041).
The strongest evidence for linkage was obtained at 20p11-q13.13 (bin 20_3) with an empirical P-value for the SRs (P SR ) of 0.0044. The region 6p21.1-6q15 (bin 6_3) also shows suggestive evidence for linkage to SLE (P SR ¼ 0.0056). This result is further strengthened by the fact that the adjacent bin (6_2) shows consistent results from the SR (P SR ¼ 0.0099) and ordered rank (P OR ¼ 0.0259). Another region with empirical P SR o0.01 is observed at 16p13-q12.2 (bin 16_2, P SR ¼ 0.0087). All three regions showed some evidence of linkage in adjacent bins with P SR o0.05 (bin 20_3: P SR ¼ 0.0450; bin 6_4: P SR ¼ 0.0328; bin 16_3: P SR ¼ 0.0451). We also found nominal evidence for linkage to SLE at the region 3p14.1-q12.3 (bin 3_4), where both P SR and P OR o0.05.
In the GSMA on the subgroup of five Caucasian studies, three bins yielded suggestive evidence for linkage (empirical P SR evaluated through simulation o0.0078), in particular bin 3_6 (P SR ¼ 0.0046), bin 7_6 (P SR ¼ 0.0071) bin 10_2 (P SR ¼ 0.0077). For the most significant bin (bin 3_6, cytogenetic band 3q22.1-q25.31) or for the flanking bin 3_7 (cytogenetic band 3q25.31-q27.3), where a P SR of 0.0266 was obtained, individual studies have shown evidence of linkage, in particular in Caucasian families, 12, 18, 19 although only of marginal significance. GSMA thus provided greater power to identify the region that showed only weak evidence for linkage in individual studies.
It is notable that the regions identified in the Caucasian analysis differ from those providing the strongest evidence of linkage in the analysis of all families, which include substantial numbers (43%) of families from other ethnic backgrounds (Table 2 ). This finding is consistent with genetic heterogeneity related to ethnicity, as suggested by a number of recent linkage analyses. 21, 22 Sensitivity analyses in which both the all-ethnicity and Caucasian analyses were performed with different weighting schemes did not substantially change the results (data not shown).
Among the best-supported SLE susceptibility regions exhibiting genome-wide significance levels in single studies and/or confirmed evidence in an independent sample (1q23, 1q41, 2q37, 4p16, 6p21, 11p13, 12q24 and 16q13), we obtained the strongest evidence for linkage in regions 6p21 and 16q13, suggesting that these loci have the greatest potential to contain true susceptibility genes for SLE.
Several of the loci identified in this analysis coincide with loci implicated in other autoimmune diseases, suggesting a sharing of predisposition to multiple autoimmune diseases. The presence of multiple autoimmune-predisposing genes on chromosome 20 has been recently suggested by Gaffney et al. 23 Bins 6_2 and 6_3 overlap with the human leukocyte antigen cluster (6p21.3), for which numerous association studies as well as a targeted linkage analysis involving a dense map of microsatellite markers across the region 24 support the importance of this genomic region to SLE. Bins 16_2 and 16_3 are also of interest as meta-analysis studies of two other autoimmune diseases (rheumatoid arthritis and inflammatory bowel disease) also identified this 16q region. 5, 7 In the 16q12 region, the CARD15/NOD2 gene, found to be associated with Cohn's disease, 25, 26 has also been suggested as a pleiotropic autoimmune gene that For each study, the maximum evidence for linkage within each bin was identified, and then bins were ranked accordingly. Within a bin, weighted ranks were summed across all studies. The SR of each bin forms a test statistic, which was assessed empirically against the distribution of SRs, under the null hypothesis that no susceptibility loci exist within that bin and ranks are therefore randomly assigned. Empirical significance values were obtained from 10 000 simulations, using the GSMA software 8 (http://www.kcl.ac.uk/depsta/memoge/ gsma/). A bin with a high SR indicates evidence for linkage across several studies. P-values in bold denote suggestive evidence for linkage (PSRo0.0083). Ordered rank P-values (POR) were also derived, as recent simulation studies indicate that bins with both PSRo0.05 and P OR o0.05 have the highest probability of containing a gene. 4 We estimated genome-wide significance through simulation by randomly reshuffling the observed ranks within each study 10 000 times and deriving for each meta-analysis simulated under the null hypothesis of no linkage, the minimum P-value. Empirical P-values for suggestive linkage, which is expected by chance only once per GSMA, was estimated from the mean among the minimum observed P-values, whereas genome-wide significance, expected to occur 0.05 times per GSMA, was estimated from the 5% lowest observed P-value. This procedure was performed for all studies and for Caucasian studies, and no correction for multiple testing across datasets was applied. d Results obtained in the Lee and Nath 29 study for the regions identified in the current GSMA.
SLE linkage meta-analysis P Forabosco et al may be involved in the common etiology of other diseases. 27, 28 It is of interest to compare our results to those of a recent GSMA performed by Lee and Nath. 29 There are a number of methodological differences, including the fact that only the most significant results derived from tables were ranked in the analysis by Lee and Nath, 29 resulting in a large amount of missing data. Use of only the top results does not bias the GSMA analysis, provided that significance is evaluated by simulation, 3 however, it reduces the power to detect linkage, especially for those regions whose genetic effect is too small to be identified with high significance by a single study. Our study therefore provides a more through analysis with genome wide data available for almost all studies ( Table 2 ). In the Caucasian studies we found evidence for linkage in three regions (3q22.1-q25.31, 7q34-qter and 10p14-q11.21), whereas Lee and Nath 29 found only marginal evidence was obtained on chromosomes 3 and 7 (P SR ¼ 0.01376 and P SR ¼ 0.03915, respectively, see Table 2 ). Within the chromosome 10 region identified in the Caucasian samples is the MBL gene [MIM:154545] (mannosebinding protein gene) for which dysfunctional variants have been associated in several SLE studies. 30 Another difference is that we analyzed pooled studies from each research center, whereas Lee and Nath considered the tabulated results obtained for each ethnic group, or for multiple stages of the analyses, giving 12 studies in total. This difference is likely to affect the strength of the significance, as significance of the GSMA is highly dependent on the number of studies included. Nevertheless, there are a number of consistencies in the results of the two meta-analyses. In particular, the regions on chromosomes 6, 16 and 20 were identified in both analyses, thus strengthening the evidence for the presence of SLE genetic factors. Although less significant evidence for the chromosome 6 and 16 regions were obtained in the current study, this is likely owing to the methodological differences mentioned above. Finally, concordant nominal evidence for linkage was also found at bin 2_8 (cytogenetic band 2q31.1-q34, P SR ¼ 0.0268).
In summary, this GSMA of SLE families identifies the genomic regions providing the most compelling evidence for linkage to SLE, based on the currently available data. This information, in conjunction with other data emerging from dense single nucleotide polymorphism typing of specific regions and/or future genome-wide association studies will help guide efforts to identify the actual predisposing genetic variation contributing to this complex genetic disease.
